The Polycomb transcription repressor BMI1 is highly expressed in human neuroblastomas and is required for the clonogenic self-renewal and tumorigenicity of human neuroblastoma cell lines. The molecular basis of BMI1 action in neuroblastoma cells is not well understood. Here we report that BMI1 has a critical role in stabilizing cyclin E1 by repressing the expression of FBXW7, a substrate-recognition subunit of the SCF E3 ubiquitin ligase that targets cyclin E1 for degradation. BMI1 binds to the FBXW7 locus in vivo and represses its mRNA expression. Overexpression of cyclin E1 or abrogation of FBXW7 induction rescues the cell-death phenotype of BMI1 knockdown. Moreover, MYCN, an oncoprotein in the pathogenesis of high-risk neuroblastomas, is able to counteract the death-inducing effect of BMI1 knockdown by activating CCNE1 transcription. We further show that high cyclin E1 expression is associated with Stage 4 neuroblastomas and poor prognosis in patients. These findings suggest a molecular mechanism for the oncogenic activity of BMI1 and MYCN in neuroblastoma pathogenesis and progression by maintaining cyclin E1 levels.
Introduction
BMI1 is a member of the Polycomb group family of transcriptional repressors that was originally identified as an oncogenic partner of c-Myc in murine lymphomagenesis (Haupt et al., 1991; van Lohuizen et al., 1991) . It is a component of the Polycomb repressive complex 1 required for transcriptional repression of genes important in development and differentiation (Valk-Lingbeek et al., 2004; Schwartz and Pirrotta, 2007; Sauvageau and Sauvageau, 2010) . BMI1 has diverse biological functions as demonstrated by phenotypic analysis of Bmi1 À/À mice. These mice display defects in axial skeleton patterning, hematopoiesis and neural development (van der Lugt et al., 1994) . Later studies have revealed a critical role of BMI1 in the selfrenewal of normal and cancer stem cells (Lessard and Sauvageau, 2003; Molofsky et al., 2003; Park et al., 2003; Iwama et al., 2004) .
A key downstream target of BMI1 is the Ink4a-ARF locus that encodes two tumor suppressors, p16 Ink4a and p14 ARF (p19 ARF in the mouse; Jacobs et al., 1999a; Park et al., 2004) . p16 Ink4a inhibits the cyclin D-CDK4/6 kinase responsible for phosphorylation of pRb during the cell cycle. The resulting hypophosphorylated pRb binds E2F and represses its transcriptional activation of the genes that promote S-phase entry, leading to cell cycle arrest and senescence. p14 ARF inhibits MDM2, which targets p53 for ubiquitin-dependent degradation, leading to accumulation of p53 and transcriptional activation of its target genes that promote cell cycle arrest, senescence and apoptosis (Lowe and Sherr, 2003) . Importantly, inactivation of the Ink4a-ARF locus or individual p16 Ink4a and p19 ARF partially rescues the self-renewal and frequency of stem cells in the central and peripheral nervous systems in Bmi1 À/À mice (Molofsky et al., 2003 (Molofsky et al., , 2005 Bruggeman et al., 2005) , demonstrating that repression of the Ink4a-ARF locus is critical for Bmi1 to maintain stem cells. However, the partial rescue of Bmi1 À/À phenotype by ablation of p16 Ink4a and p19 ARF also suggests the involvement of additional target genes for the biological functions of BMI1.
BMI1 is highly expressed in human neuroblastomas and neuroblastoma cell lines (Cui et al., 2006 (Cui et al., , 2007 Nowak et al., 2006; Ochiai et al., 2010) . Neuroblastoma is a common childhood malignant tumor of the sympathetic nervous system that arises in paravertebral sympathetic ganglia and the adrenal medulla (Brodeur, 2003) . Both tissues originate from neural crest cells, a transient, highly migratory population of multipotent stem cells that require BMI1 for their self-renewal (Molofsky et al., 2003 (Molofsky et al., , 2005 . We have recently demonstrated an essential role of BMI1 in the maintenance of the clonogenic self-renewal and tumorigenicity of human neuroblastoma cell lines (Cui et al., 2006 (Cui et al., , 2007 . Moreover, we have shown that Bmi1 cooperates with MYCN in transformation of avian neural crest cells by inhibiting the pro-apoptotic activity of MYCN (Cui et al., 2007) . Amplification of the oncogene MYCN, which occurs in B22% of neuroblastoma cases, is strongly associated with highly malignant behavior and poor prognosis (Maris and Matthay, 1999; Brodeur, 2003; Schwab, 2004) .
In this report, we present evidence for cyclin E1 as a common downstream target of BMI1 and MYCN in promoting the survival of neuroblastoma cells. MYCN transcriptionally activates the expression of cyclin E1, whereas BMI1 represses the transcription of FBXW7 to block cyclin E1 degradation. These findings provide a molecular mechanism for maintaining high cyclin E1 expression, which is associated with poor outcome and disease progression in neuroblastoma patients.
Results
Individual neuroblastoma cells display differential sensitivities to BMI1 knockdown To investigate the molecular basis of BMI1 action in neuroblastoma cells, we used an RNAi-based approach for knockdown of BMI1 expression in BE(2)-C cells, a human neuroblastoma cell line enriched for cells capable of clonogenic self-renewal in a BMI1-dependent manner (Cui et al., 2006) . We tested four retroviral constructs expressing shRNA sequences against different regions of the human BMI1 gene, and two of them (BMI1sh-48576 and-48580) were highly effective in knockdown of BMI1 expression ( Supplementary Figure 1a ) and had a similar inhibitory effect on tumor cell clonogenicity (Supplementary Figure 1b ). These findings confirmed our previous observation of a critical role of BMI1 in maintaining the clonogenicity of neuroblastoma cells (Cui et al., 2006 (Cui et al., , 2007 and demonstrated the functional specificity of these BMI1 shRNA sequences.
As BMI1 is critical for maintaining the clonogenicity of neuroblastoma cells (Cui et al., 2006 (Cui et al., , 2007 , constitutive knockdown of BMI1 may select a minor population of BE(2)-C cells that either fail to express BMI1 shRNA or acquire additional genetic or epigenetic mutations to bypass the requirement of BMI1. To minimize this possibility, we generated a 'Tet-Off' system for inducible expression of the BMI1sh-48576 sequence in BE(2)-C cells and conducted our investigation either with single-cell-derived clones or with a pool of these clones. We examined 20 single-cell-derived clones that showed marked downregulation of BMI1 protein levels in the absence of doxycycline. Approximately two-third of these clones (n ¼ 14) were relatively resistant to BMI1 knockdown (referred to below as BMI1-resistant clones). As represented by clone-7 and -12 cells, BMI1 knockdown had no apparent effect on their proliferation in culture (Figures 1a and b ), but significantly reduced their ability to grow in soft agar, as judged by both the number and size of colonies ( Figure 1c ). By contrast, cells of the remaining 6 clones (numbers 2, 9, 11, 15, 20 and 22) were extremely sensitive to BMI1 knockdown (referred to below as BMI1-sensitive clones), showing a marked decrease in clonogenicity (Figures 1d-e ). Following BMI1 knockdown, these cells progressively rounded up and detached from the culture matrix (Figures 1f-g) . The cell death phenotype induced by the BMI1sh-48576 sequence, which targets the 3 0 -untranslated region of human BMI1 mRNA ( Supplementary Figure 2a ), could be effectively rescued by retroviral expression of the BMI1 coding sequence ( Supplementary Figures 2b and c) , demonstrating that the effect is a result of BMI1 silencing. Together, these findings reveal differential sensitivities of individual BE(2)-C cells to the reduction in BMI1 levels.
BMI1 knockdown induces non-apoptotic cell death independently of p16 Ink4a and p14 ARF We next focused our investigation on the cell deathinducing effect of BMI1 knockdown. It has been shown previously that BMI1 can promote cell survival by suppressing apoptosis (Jacobs et al., 1999b; Yamashita et al., 2008) . However, the majority of the dying cells following BMI1 knockdown displayed no morphologic features of apoptosis, such as cell shrinkage and membrane blebbing ( Figure 1f ). Propidium iodide flow cytometry analysis of BMI1-sensitive clone-2 and -9 cells following BMI1 knockdown revealed no significant numbers of cells with sub-G1 DNA content (Supplementary Figure 3a ), a characteristic of apoptotic cells (Riccardi and Nicoletti, 2006) . We also observed no significant levels of membrane annexin V staining during BMI1 knockdown-induced cell death (Supplementary Figure 3b ). Annexin V binds externalized phosphatidylserine on the plasma membrane, an early event in apoptosis (Martin et al., 1995) . Finally, treatment of clone-2 and -9 cells with the cell permeable pan-caspase inhibitor zVAD-FMK failed to prevent BMI1 knockdown-induced cell death although it was highly effective in protecting cells from Fas-mediated apoptosis ( Supplementary Figure 3c ). Together, these data indicate that BMI1 knockdown induces predominantly non-apoptotic cell death in a subset of neuroblastoma cells.
The isolation of neuroblastoma cell clones that were dependent on BMI1 for survival provided a highly sensitive functional assay system for the identification of relevant BMI1 downstream target genes. We first examined p16 Ink4a and p14 ARF , two well-documented target genes of BMI1 (Valk-Lingbeek et al., 2004; Sauvageau and Sauvageau, 2010) . BMI1 knockdown had no significant effect on p16 Ink4a protein levels but did result in a marked increase in the protein levels of p14 ARF (Supplementary Figure 4a ). However, overexpression of p14 ARF in both clone-2 and -9 cells (in the absence of BMI1 knockdown) had no effect on their survival and proliferation in soft agar and in culture ( Supplementary  Figures 4b-d ). Together, these results indicate that BMI1 knockdown induces non-apoptotic cell death in a manner independent of p16 Ink4a and p14 ARF .
BMI1 suppresses non-apoptotic cell death by maintaining cyclin E1 levels
The observation that BMI1 knockdown led to an accumulation of S-phase cells (Supplementary Figure   Figure 1 Individual BE(2)-C neuroblastoma cells display differential sensitivities to BMI1 knockdown. (a) Immunoblot analysis of BMI1 levels in clone-7 and -12 cells cultured in the presence or absence of doxycycline (Doxy) for 3 days. BMI1 levels were quantified against atubulin and are presented as the fraction of the BMI1 level in the presence of Doxy. (b) Phase contrast imaging of clone-7 and -12 cells cultured in the presence or absence of Doxy for 10 days. Scale bars, 100 mm. (c) Soft agar clonogenic assay of clone-7 and -12 cells in the presence or absence of Doxy. Numbers of total colonies and of the colonies that were >0.5 mm were determined (error bars, s.d., n ¼ 3). (d) Immunoblot analysis of BMI1 levels in BMI1-sensitive clones cultured in the presence or absence of Doxy for 3 days. BMI1 levels were quantified against a-tubulin and are presented as the fraction of the BMI1 level in the presence of Doxy. (e) Soft agar clonogenic assay of parental and luciferase shRNA-expressing BE(2)-C cells, and BMI1-sensitive clones in the presence or absence of Doxy. Numbers of total colonies were determined (error bars, s.d., n ¼ 3). All quantitative data from soft agar assays were analyzed using two-tailed Student's t-test with the P-values indicated. (f) Phase contrast imaging of BMI1-sensitive clones cultured in the presence or absence of Doxy for 3 days. (g) Phase contrast imaging of the clone-2 cells cultured in the absence of Doxy for 0-6 days. Scale bars (f-g), 100 mm. 3a) prompted us to examine the effect BMI1 knockdown on the expression of major components of the cell cycle machinery in BMI1-sensitive cells. Immunoblotting analysis revealed that BMI1 knockdown consistently resulted in a rapid and marked decrease in cyclin E1 levels, but had no or modest effect on the levels of other cyclins and CDKs (Figure 2a and Supplementary Figure  5a Figure 5b ). These data demonstrate that maintaining cyclin E1 levels is a major mechanism for the pro-survival activity of BMI1.
Quantitative reverse-transcription-PCR revealed that BMI1 knockdown had no effect on cyclin E1 mRNA levels ( Figure 2f ), but led to a marked decrease (3.2-6.7fold) in its protein half-life ( Figure 2g and Supplementary Figure 5c ). Consistent with this result was our observation that BMI1 knockdown resulted in a marked increase in the level of cyclin E1 polyubiquitination ( Figure 2h ). Together, these data indicate that BMI1 maintains cyclin E1 levels by blocking its degradation.
BMI1 stabilizes cyclin E1 by repressing the expression of FBXW7
We next examined the molecular mechanism by which BMI1 maintains cyclin E1 levels. Two E3 ubiquitin ligases, the SKP/CUL/F-box (SCF) protein complex and the anaphase-promoting complex/cyclosome, are responsible for ubiquitination of cyclins. The specificity is conferred by substrate-recognition subunits of these (g) Quantification of cyclin E1 half-life in pooled BMI1-sensitive clones cultured in the presence or absence of Doxy for 3 days. Samples were collected at various time points following addition of cycloheximide (CHX) for immunoblot analysis. Cyclin E1 levels were quantified against a-tubulin and are presented as the fraction of the initial levels at time zero (error bars, s.d., n ¼ 4). (h) In vivo ubiquitination assay of pooled BMI1-sensitive cells cultured in the presence or absence of Doxy for 3 days and co-transfected with Flag-ubiquitin and Myc-cyclin E1 expression plasmids. Polyubiquitinated cyclin E1 was detected by immunoprecipitation of Myc-cyclin E1, followed by immunoblotting for Flag-ubiquitin. complexes, including SKP2 (cyclins A, D and E), FBXW7 (cyclin E), CDC20 (cyclins A and B) and CDH1/FZR1 (cyclins A and B; Nakayama and Nakayama, 2006) . BMI1 knockdown significantly increased the mRNA level of FBXW7, but had no effect on the mRNA level of SKP2 ( Figure 3a ). In addition, chromatin immunoprecipitation and quantitative PCR assays revealed a locus-wide association of BMI1 with the FBXW7 gene including the proximal promoter region (À1 kb to the transcription start site) and all FBXW7 introns (Figure 3b ). Thus, FBXW7 is a direct target gene of BMI1. Moreover, abrogation of FBXW7 induction by shRNA restored cyclin E1 levels and rescued the cell-death phenotype of BMI1 knockdown (Figures 3c-e and Supplementary Figure 6 ). Collectively, these results indicate that BMI1 suppresses cell death by directly repressing FBXW7 expression to maintain cyclin E1 levels in neuroblastoma cells.
MYCN counteracts the effect of BMI1 knockdown by activating cyclin E1 transcription
It was recently reported that FBXW7 can ubiquitinate MYCN, thereby targeting it for degradation (Otto et al., 2009) . This prompted us to investigate whether FBXW7 induction, as a result of BMI1 knockdown, could lead to downregulation of MYCN in BE(2)-C cells, which carry MYCN amplification and express significant levels of MYCN protein (Cui et al., 2007) . Surprisingly, im-munoblot analysis revealed that all BMI1-sensitive clones expressed no detectable levels of MYCN, even in the absence of BMI1 knockdown (Figure 4a , clone-2 and -9 and Figure 4d , pooled clones). This was in contrast to parental, Tet repressor-expressing and BMI1-resistant BE(2)-C cells, which all expressed high levels of MYCN (Figure 4a ). BMI1 knockdown in the resistant clone-7 and -12 cells was able to upregulate FBXW7 mRNA levels but had no significant effect on MYCN and cyclin E1 protein levels (Figures 4b and c) . Also interesting was the observation that when pooled BMI1-sensitive cells were cultured under the condition of BMI1 knockdown for an extended period of time, a minor population of cells survived and eventually became proliferative again. These cells showed reexpression of MYCN and cyclin E1 (Figure 4d ), indicating a selective pressure for upregulation of MYCN and cyclin E1 when the BMI1 level is low. In addition, overexpression of MYCN in BMI1-sensitive cells effectively prevented cyclin E1 downregulation and cell death induced by BMI1 knockdown (Figures 4e  and f and Supplementary Figure 7) . These observations demonstrate that MYCN confers resistance to BMI1 knockdown and provide a molecular mechanism for the differential sensitivities of individual BE(2)-C cells to BMI1 knockdown. This conclusion was further supported by studies with additional human neuroblastoma cell lines. SK-N-DZ and SK-N-F1 cells expressed high and no detectable levels of MYCN, respectively ( Supplementary Figure 8a) . BMI1 knockdown was able to upregulate FBXW7 mRNA levels in both cell lines ( Supplementary Figure 8b) . However, only SK-N-F1 cells were sensitive to BMI1 knockdown, showing significant cyclin E1 downregulation and cell death ( Supplementary Figures 8a and c) .
It is well documented that MYC proteins can transcriptionally activate cyclin E1 expression, either directly or indirectly (Jansen-Durr et al., 1993; Steiner et al., 1995; Perez-Roger et al., 1997) . Consistent with these earlier findings, overexpression of MYCN in SHEP1 neuroblastoma cells, which express very low levels of endogenous MYCN (Cui et al., 2005) , upregulated cyclin E1 at both the mRNA and protein levels (Figures 5a and  b) . Also, primary human neuroblastomas with MYCN amplification expressed significantly higher levels of cyclin E1 mRNA than neuroblastomas without MYCN amplification (Figure 5c ). Together, these findings suggest that MYCN counteracts the effect of BMI1 knockdown by activating CCNE1 transcription.
High cyclin E1 expression is prognostic for poor outcome and disease progression in neuroblastoma patients
As both BMI1 and MYCN target cyclin E1 to promote the survival of neuroblastoma cells, we investigated the possibility of cyclin E1 as a prognostic marker for disease progression and clinical outcomes in neuroblastoma patients. Kaplan-Meier analysis of progressionfree survival for the Oberthuer data set, which includes a cohort of 251 neuroblastoma patients (Oberthuer et al., 2006) , showed that high cyclin E1 expression was associated with poor outcome, whereas low HOXC9 expression was associated with good prognosis (Figure 6a ). We confirmed that high cyclin E1 expression is prognostic for unfavorable outcome with the Khan data set (Figure 6b ), which includes a cohort of 56 neuroblastoma patients (Wei et al., 2004; Chen et al., 2008) . Importantly, in both data sets, only Stage 4 tumors displayed significantly higher levels of cyclin E1 expression (Figures 6c and d) , demonstrating a positive correlation between cyclin E1 expression levels and tumor progression. Together, our analysis of two 
Discussion
BMI1 is highly expressed in human neuroblastomas and neuroblastoma cell lines and is essential for the clonogenic self-renewal and tumorigenicity of neuroblastoma cells (Cui et al., 2006 (Cui et al., , 2007 Nowak et al., 2006) , suggesting a critical role of BMI1 in neuroblastoma development. By examining the sensitivity of single-cell-derived clones to BMI1 knockdown, our study has revealed a pro-survival activity of BMI1 in suppression of non-apoptotic cell death in neuroblastoma cells. This action of BMI1 depends on its ability to maintain cyclin E1 levels by directly repressing the expression of FBXW7, which targets cyclin E1 for ubiquitination and degradation. We further show that MYCN, an oncoprotein critical in the pathogenesis of high-risk neuroblastomas (Maris and Matthay, 1999; Brodeur, 2003; Schwab, 2004) , is able to counteract the effect of BMI1 knockdown by activating cyclin E1 transcription. Thus, BMI1 and MYCN maintain cyclin E1 levels in neuroblastoma cells through distinct mechanisms: MYCN transcriptionally activates the expression of cyclin E1, whereas BMI1 represses the transcription of FBXW7 to block cyclin E1 degradation (Figure 7) . In this regard, it is interesting to note that a recent study has identified BMI1 as a direct target gene of MYCN (Ochiai et al., 2010) , suggesting a mechanism for reinforcing and maintaining cyclin E1 levels in neuroblastoma cells. These findings identify cyclin E1 as a common target of two important oncogenic pathways in the pathogenesis of neuroblastoma.
Our study has also revealed that high cyclin E1 expression is significantly associated with Stage 4 tumors and poor outcome, suggesting an important role of cyclin E1 in neuroblastoma progression. Cyclin E1 is known as a positive regulator of G1/S transition, DNA replication and S-phase progression (Hwang and Clurman, 2005; Satyanarayana and Kaldis, 2009 ). Cyclin E1-CDK2 phosphorylates and inactivates pRb, leading to the release of E2F, which in turn promotes S-phase entry. Cyclin E1 also has a critical role in the binding of MCM proteins to replication origins and in centrosome duplication. Moreover, high cyclin E1 expression promotes genetic instability and aneuploidy (Spruck et al., 1999; Minella et al., 2002) , which is generally thought to contribute to tumor progression by increasing genetic diversity among tumor cells (Thompson et al., 2010) . In this study, we have identified an essential role of cyclin E1 in the survival of neuroblastoma cells. Thus, cyclin E1 could promote neuroblastoma progression through multiple mechanisms. Together, these findings suggest that maintenance of cyclin E1 levels is likely an important mechanism for the oncogenic activity of BMI1 and MYCN in neuroblastoma pathogenesis and progression.
Previous studies have shown that BMI1 can promote cell survival by suppressing apoptosis, which is mediated, at least in part, through the ARF-MDM2-p53 pathway (Jacobs et al., 1999a; Park et al., 2004) . Although BMI1 knockdown in BE(2)-C cells resulted in a marked increase in the protein levels of p14 ARF , these cells carry mutated p53 (Kaghad et al., 1997) . This may be one of the reasons why BMI1 knockdown failed to induce apoptosis in BE(2)-C cells. Probably as a result, we were able to identify a novel mechanism by which BMI1 promotes cell survival by maintaining the cyclin E1 levels. The molecular basis for cyclin E1 depletioninduced non-apoptotic cell death in neuroblastoma cells remains to be determined. Notably, cyclin E1 knockdown resulted in a marked increase in the number of S-phase cells. Given the critical role of cyclin E1 in the control of DNA replication (Hwang and Clurman, 2005; Satyanarayana and Kaldis, 2009) , we speculate that depletion of cyclin E1 may lead to an accumulation of the cells with incomplete DNA synthesis, which is known to trigger replication stress and non-apoptotic cell death (Ma et al., 2011) . Regardless of mechanistic details, our observations that high cyclin E1 expression is associated with Stage 4 neuroblastomas, particularly those with MYCN amplification, and is essential for the survival of neuroblastoma cells provide a strong rationale for targeting cyclin E1 as a therapeutic strategy for high-risk neuroblastomas.
FBXW7 is a general tumor suppressor and loss-offunction mutations of FBXW7 have been identified in B6% of human cancers (Onoyama and Nakayama, 2008; Welcker and Clurman, 2008; Crusio et al., 2010) . In addition to cyclin E1, a large number of oncoproteins has been identified as the substrates of FBXW7, including Notch, c-MYC, c-Jun, Aurora A, GSK3-b, c-Myb and mTor. More recently, it has been shown that FBXW7 is able to ubiquitinate MYCN and target it for degradation (Otto et al., 2009 ), suggesting a potential tumor suppressor function for FBXW7 in neuroblastoma development. By repressing FBXW7 expression, BMI1 may stabilize these oncoproteins, and some of them might function as downstream effectors of BMI1 in promoting the clonogenic self-renewal and tumorigenicity of neuroblastoma cells. For example, inhibition of Notch signaling induces growth arrest and differentiation of neuroblastoma cells (Chang et al., 2010; Ferrari-Toninelli et al., 2010) , suggesting a critical role of Notch signaling in the maintenance of the stem cell or progenitor state of neuroblastoma cells. In addition to neuroblastoma pathogenesis, we speculate that BMI1mediated repression of FBXW7 may represent a common oncogenic mechanism in cancer development.
Materials and methods

Cell culture
The human neuroblastoma cell lines BE(2)-C (CRL-2268, ATCC, Manassas, VA, USA), SK-N-DZ (CRL-2149, ATCC) and SK-N-F1 (CRL-2141, ATCC) were cultured in Dulbecco's modified Eagle's medium and Ham's nutrient mixture F12 (1:1) supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA). BE(2)-C, SK-N-DZ and SK-N-F1 cells with a Tet-Off inducible system were established as described previously (Mao et al., 2011) . Cells were examined and phase contrast images captured using an Axio Observer microscope and AxioVision software (Carl Zeiss MicroImaging, Thornwood, NY, USA).
Overexpression and RNA interference
Human cDNAs for BMI1 (Cui et al., 2006) , MYCN (Cui et al., 2005) , p14 ARF (Wei et al., 2001) , CCNE1 and FBXW7 (Open Biosystems, Huntsville, AL, USA) were cloned into the retroviral vector pBabe-hygro. The green fluorescent protein retroviral construct pBabe-hygro-green fluorescent protein was (pSM2) constructs expressing shRNA to human BMI1 (RHS4529-NM_005180) were purchased from Open Biosystems and the shRNA-coding sequences were subcloned into the retroviral shRNAmir Tet-Off vector (Silva et al., 2008) for inducible expression. The luciferase shRNAmir Tet-Off construct was used as a control. Retroviruses were produced in 293FT cells using the packaging plasmids pHDM-G and pMD.MLVogp. Lentiviral constructs expressing shRNA to human FBXW7 (RHS4533-NM_ 001013435) were purchased from Open Biosystems and to green fluorescent protein (pLKO.1-green fluorescent proteinshRNA) from Addgene (Cambridge, MA, USA). Lentiviruses were produced in 293FT cells using the packaging plasmids pLP1, pLP2 and pLP/VSVG (Invitrogen).
Immunoblot analysis
Immunoblotting was conducted according to the standard procedures using the following primary antibodies: mouse anti-BMI1 ( , 1997-2011) . Films were exposed for various times for quantification of target proteins within their linear range of detection. Whenever possible, protein levels were also quantified using the Odyssey system and software (LI-COR Biosciences, Lincoln, NE, USA).
Quantitative reverse-transcription-PCR Cells were lysed with Trizol (Invitrogen) for total RNA purification. Reverse transcription was performed using SuperScript II Reverse Transcriptase (Invitrogen). PCR in triplicate was performed using an iQ5 real-time PCR system (Bio-Rad, Hercules, CA, USA), a TaqMan gene expression assay kit (Applied Biosystems, Foster City, CA, USA) and the following TaqMan probe and primers: cyclin A2 (Hs00153138_m1), cyclin B1 (Hs00259126_m1), cyclin D1 (Hs00277039_m1), cyclin E1 (Hs00233356_m1), cyclin E2 (Hs00180319_m1), FBXW7 (Hs00217794_m1), SKP2 (Hs001806634_m1) and GAPDH (Hs99999905_m1).
Fluorescence-activated cell sorting
For cell cycle analysis, cells were fixed with 70% ethanol, incubated with ribonuclease A (Sigma-Aldrich) and stained with 20 mg/ml propidium iodide (Invitrogen). Annexin V staining was performed using a PE Annexin V Apoptosis Detection Kit (BD Pharmingen, San Diego, CA, USA). Samples were analyzed with a FACSCalibur system (BD Biosciences, San Jose, CA, USA) and ModFitLT V3.2.1 software (Verity Software House, Topsham, ME, USA).
Protein half-life assay
Cells with Tet-Off inducible expression of BMI1 shRNA were cultured in the presence or absence of doxycycline for 3 days, followed by addition of cycloheximide (Sigma-Aldrich) to the final concentration of 10 mg/ml. Samples were then collected at various time points for immunoblot analysis of cyclin E1 levels, which were quantified against a-tubulin using ImageJ (version 1.42q) or the Odyssey Software (LI-COR Biosciences) as described above.
In vivo ubiquitination assay Cells with Tet-Off inducible expression of BMI1 shRNA were cultured in the presence or absence of doxycycline for 2 days and transfected with pFlag-ubiquitin and pKMyc-cyclin E1. One day after transfection, cells were pre-treated with 20 mM MG-132 for 4 h, washed with PBS and lyzed with radioimmuno precipitation assay buffer containing 20 mM MG-132 and 10 mM N-Ethylmaleimide (both from Sigma-Aldrich). Lysates were cleared by centrifugation and supernatants were collected, followed by addition of sodium dodecyl sulfate to the final concentration of 1% (v/v). After boiling for 5 min to dissociate proteins, samples were diluted 1:10 with dissociation dilution buffer (50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.2, 120 mM NaCl, 1% Triton-X 100, 0.5% deoxycholate and 1 mM phenylmethylsulfonyl fluoride). Myc-cyclin E1 was immunoprecipitated with mouse anti-Myc tag (clone 4A6, Millipore) and Protein A/G Plus beads (Santa Cruz Biotechnology). Immunoprecipitates were washed and analyzed by immunoblotting as described above.
Soft agar clonogenic assay Cells (B2000/well) were mixed with 0.3% Noble agar in growth medium and plated onto six-well plates containing a solidified bottom layer (0.6% Noble agar in growth medium). After 14-21 days, colonies were stained with 5 mg/ml 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma-Aldrich), photographed and counted.
Chromatin immunoprecipitation
Anti-BMI1 chromatin immunoprecipitation was performed on pooled BMI1-senitive cells cultured in the presence or absence of doxycycline for 3 days, using a monoclonal antibody to BMI1 (clone AF27, Millipore) or control mouse immunoglobulin G according to the online protocol (http://jura.wi.mit.edu/ young_public/hESregulation/ChIP.html). Chromatin immunoprecipitation DNA in triplicate was analyzed by quantitative PCR. Primer sequences are listed in Supplementary Table 1 .
Analyses of patient data
Patient data used in this study were described previously (Asgharzadeh et al., 2006; Oberthuer et al., 2006) . Gene expression data sets were obtained from the Oncogenomics Database (http://pob.abcc.ncifcrf.gov/cgi-bin/JK; Chen et al., 2008) . Kaplan-Meier analysis was conducted online, and the resulting survival curves and P-values (log-rank test) were downloaded. All cutoff values for separating high and low expression groups were determined by the online Oncogenomics algorithm (Chen et al., 2008) .
